advanced-renal-cell-carcinoma

Documents about advanced-renal-cell-carcinoma

• Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar#1229863ClinicalTrials.gov
• CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer#481764ClinicalTrials.gov
• CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer#343844ClinicalTrials.gov
• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer#1185443ClinicalTrials.gov
• Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC#850444ClinicalTrials.gov
• Tumor Registry of Advanced Renal Cell Carcinoma#1294362ClinicalTrials.gov
• Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma#162452ClinicalTrials.gov
• First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain#1183595ClinicalTrials.gov
• A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma#1321328ClinicalTrials.gov
• RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy#1370228ClinicalTrials.gov
• A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma#887177ClinicalTrials.gov
• Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma#825813ClinicalTrials.gov
• Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)#859229ClinicalTrials.gov
• Study of ST-1898 in Advanced Renal Cell Carcinoma#1382945ClinicalTrials.gov
• Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC#877195ClinicalTrials.gov
• Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma#200217ClinicalTrials.gov
• Dendritic Cell Based Therapy of Renal Cell Carcinoma#807650ClinicalTrials.gov
• Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma#1007478ClinicalTrials.gov
• Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent#848727ClinicalTrials.gov
• Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan#852593ClinicalTrials.gov
• A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma#911182ClinicalTrials.gov
• A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)#1431004ClinicalTrials.gov
• Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma#878720ClinicalTrials.gov
• Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)#1440464ClinicalTrials.gov
• First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma#1350651ClinicalTrials.gov
• Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma#279490ClinicalTrials.gov
• UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma#1352644ClinicalTrials.gov
• Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial#140997ClinicalTrials.gov
• Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma#911956ClinicalTrials.gov
• IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma#1376712ClinicalTrials.gov
• Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma#474779ClinicalTrials.gov
• Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma#1057782ClinicalTrials.gov
• 177LuPSMA in Renal Cell Carcinoma#1174088ClinicalTrials.gov
• Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer#349958ClinicalTrials.gov
• Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment#1409848ClinicalTrials.gov
• A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma#992988ClinicalTrials.gov
• Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer#241597ClinicalTrials.gov
• Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma#878757ClinicalTrials.gov
• Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma#1095645ClinicalTrials.gov
• Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.#1309930ClinicalTrials.gov
• Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial#1365001ClinicalTrials.gov
• Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer#1138577ClinicalTrials.gov
• Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma#426786ClinicalTrials.gov
• Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer#1372087ClinicalTrials.gov
• Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma#830752ClinicalTrials.gov
• Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma#870035ClinicalTrials.gov
• Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2#1162720ClinicalTrials.gov
• Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma#1163547ClinicalTrials.gov
• Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer#837252ClinicalTrials.gov
• Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)#867149ClinicalTrials.gov